MAP2K7 and cancer: Combination therapy with MEK plus BRAF inhibitors could improve therapeutic outcomes in BRAF-mutated cancers and delay or prevent drug resistance, also be superior to monotherapy in terms of efficacy without significant increase in toxicity (Richman et al., 2015; Subbiah et al., 2020).